Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.139, Iss.1, 2013-05, pp. : 39-49

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PIK3CA mutations in breast cancer are associated with poor outcome

By Li Shao Rong Minna Grieu Fabienne Iacopetta Barry

Breast Cancer Research and Treatment, Vol. 96, Iss. 1, 2006-03 ,pp. : 91-95

Springer Publishing Company

Access to resources Recommend Favorite

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer

By Riemsma Rob

Breast Cancer Research and Treatment, Vol. 123, Iss. 1, 2010-08 ,pp. : 9-24

Springer Publishing Company

Access to resources Recommend Favorite

Aromatase Inhibitors as First Line Treatment: Treatment Cascade After Failure of Aromatase Inhibitors

By Bonneterre Jacques

Breast Cancer Research and Treatment, Vol. 81, Iss. 1, 2003-01 ,pp. : 57-61

Springer Publishing Company

Access to resources Recommend Favorite

Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer

Molecular Medicine Reports, Vol. 12, Iss. 1, 2015-01 ,pp. : 1219-1224

Spandidos Publications

Access to resources Recommend Favorite

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas

Oncology Letters, Vol. 7, Iss. 6, 2014-01 ,pp. : 2019-2022

Spandidos Publications

Access to resources Recommend Favorite